Your browser is no longer supported. Please, upgrade your browser.
CNCE Concert Pharmaceuticals, Inc. monthly Stock Chart
CNCE [NASD]
Concert Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.58 Insider Own1.00% Shs Outstand31.55M Perf Week4.70%
Market Cap337.58M Forward P/E- EPS next Y-3.10 Insider Trans-5.57% Shs Float25.36M Perf Month3.08%
Income-72.90M PEG- EPS next Q-0.78 Inst Own70.80% Short Float3.03% Perf Quarter19.56%
Sales7.90M P/S42.73 EPS this Y-37.30% Inst Trans0.01% Short Ratio5.75 Perf Half Y16.74%
Book/sh4.06 P/B2.80 EPS next Y-21.20% ROA-44.80% Target Price- Perf Year57.48%
Cash/sh4.28 P/C2.65 EPS next 5Y- ROE-55.20% 52W Range5.47 - 13.09 Perf YTD23.25%
Dividend- P/FCF- EPS past 5Y-10.40% ROI-77.80% 52W High-13.14% Beta0.75
Dividend %- Quick Ratio18.50 Sales past 5Y-34.00% Gross Margin- 52W Low107.86% ATR0.66
Employees70 Current Ratio18.50 Sales Q/Q14910.00% Oper. Margin- RSI (14)60.28 Volatility5.35% 6.70%
OptionableYes Debt/Eq0.00 EPS Q/Q17.00% Profit Margin- Rel Volume0.59 Prev Close11.02
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume133.70K Price11.37
Recom1.80 SMA206.46% SMA505.35% SMA20014.85% Volume78,315 Change3.22%
Mar-30-20Initiated Jefferies Buy $23
Oct-03-19Reiterated H.C. Wainwright Buy $29 → $25
Jun-24-19Initiated SunTrust Buy $30
Jun-13-19Upgrade Janney Neutral → Buy
Jun-13-19Reiterated H.C. Wainwright Buy $26 → $29
Sep-13-18Initiated Janney Neutral
Mar-09-18Upgrade Mizuho Neutral → Buy $23 → $27
Jan-12-18Downgrade Mizuho Buy → Neutral $23
Oct-26-17Initiated Mizuho Buy $23
Jul-24-17Initiated H.C. Wainwright Buy $20
Mar-07-17Reiterated Stifel Buy $21 → $31
Jul-01-16Initiated Stifel Buy $23
Sep-22-15Reiterated ROTH Capital Buy $22 → $32
Aug-12-15Initiated Brean Capital Buy $21
Nov-12-14Reiterated ROTH Capital Buy $28 → $21
Mar-10-14Initiated UBS Buy $25
Nov-09-20 07:00AM  
Nov-06-20 04:01PM  
Nov-05-20 06:30AM  
06:00AM  
Nov-03-20 07:00AM  
Nov-01-20 08:57AM  
Oct-29-20 10:00AM  
07:00AM  
Oct-22-20 07:00AM  
Oct-13-20 07:00AM  
Sep-29-20 07:00AM  
Sep-08-20 07:00AM  
Aug-18-20 06:00AM  
Aug-12-20 08:06AM  
Aug-06-20 11:05AM  
07:00AM  
Jul-30-20 12:33PM  
07:00AM  
Jul-08-20 07:00AM  
Jul-06-20 11:44AM  
09:30AM  
Jun-30-20 12:00PM  
11:30AM  
Jun-24-20 10:39AM  
Jun-12-20 04:01PM  
May-26-20 07:00AM  
May-22-20 08:52AM  
May-12-20 09:14PM  
07:00AM  
May-01-20 12:30AM  
Apr-30-20 08:45AM  
07:00AM  
Apr-29-20 12:00PM  
Apr-23-20 07:00AM  
Apr-15-20 08:55AM  
Apr-01-20 07:00AM  
Mar-26-20 11:54AM  
Mar-12-20 12:13AM  
Feb-24-20 07:00AM  
Feb-20-20 07:00AM  
Jan-30-20 04:01PM  
Jan-28-20 09:00AM  
Jan-27-20 04:02PM  
04:01PM  
Jan-24-20 05:52AM  
Jan-22-20 08:40AM  
Dec-19-19 04:05PM  
Dec-16-19 05:54AM  
Dec-13-19 02:18PM  
Dec-02-19 07:00AM  
Nov-25-19 11:21PM  
Nov-12-19 07:00AM  
Nov-10-19 08:40AM  
Nov-07-19 08:15AM  
07:00AM  
Nov-06-19 07:00AM  
Nov-05-19 01:36PM  
Oct-31-19 10:35AM  
07:00AM  
Oct-12-19 03:15AM  
Oct-02-19 07:00AM  
Sep-27-19 11:48AM  
Sep-23-19 07:00AM  
Sep-19-19 10:32AM  
Sep-17-19 07:00AM  
Sep-12-19 07:00AM  
Aug-29-19 07:00AM  
Aug-27-19 12:17AM  
Aug-16-19 03:10PM  
Aug-06-19 05:12AM  
Aug-01-19 09:25AM  
Jul-25-19 07:00AM  
Jul-05-19 03:12PM  
Jun-13-19 05:05PM  
Jun-12-19 07:00AM  
Jun-05-19 07:00AM  
May-28-19 02:13PM  
May-16-19 07:00AM  
May-14-19 07:00AM  
May-07-19 01:51PM  
May-02-19 11:52AM  
08:01AM  
07:00AM  
Apr-29-19 07:00AM  
Apr-25-19 10:34AM  
07:00AM  
Apr-11-19 09:46AM  
07:00AM  
Apr-10-19 06:30AM  
Apr-08-19 03:09PM  
02:45PM  
Mar-25-19 10:42AM  
Mar-12-19 08:13AM  
07:00AM  
Mar-07-19 08:40AM  
Mar-06-19 07:00AM  
Mar-05-19 04:09PM  
Mar-01-19 07:00AM  
Feb-28-19 10:49AM  
07:00AM  
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUTT PETER BARTONDirectorAug 31Option Exercise3.793,53913,4137,963Sep 01 04:01 PM
Cassella James VChief Development OfficerAug 17Sale10.374,35445,15176,127Aug 19 05:44 PM
Becker Marc A.Chief Financial OfficerAug 17Sale10.242,87529,44053,434Aug 19 05:43 PM
Stuart NancyChief Operating OfficerJun 22Option Exercise3.7921,23880,492167,924Jun 24 09:02 AM
Stuart NancyChief Operating OfficerJun 22Sale11.3410,295116,694157,629Jun 24 09:02 AM
Tung Roger DChief Executive OfficerMar 13Option Exercise3.7914,60155,338752,758Mar 16 07:23 AM
Auchincloss Thomas GDirectorMar 12Buy8.521,50012,7736,500Mar 13 12:19 PM
Auchincloss Thomas GDirectorFeb 03Buy10.911,00010,9105,000Feb 04 11:30 AM
Stuart NancyChief Operating OfficerDec 04Option Exercise4.415,89626,001104,739Dec 06 04:05 PM
Tung Roger DChief Executive OfficerDec 04Option Exercise4.4113,16658,062644,686Dec 06 04:05 PM